Health Care • Biotechnology: Pharmaceutical Preparations
$4.69 ▲ +0.34
(+7.82%)
MKT CAP: $65.2M • VOL: 129.0K
52W L $2 52W H $9
CPIX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $44.5M | $37.9M | $39.6M |
| YoY Revenue Growth % | +17.6% | -4.3% | — |
| Gross Profit | $37.9M | $31.3M | — |
| Gross Margin % | 85.0% | 82.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$2.8M | -$6.4M | -$9.6M |
| Operating Margin % | -6.3% | -17.0% | -24.2% |
| Net Income (GAAP) | -$2.8M | -$6.5M | -$6.3M |
| EBITDA (Normalized) | -$2.7M | -$6.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $4.9M | -$612.2K | $6.1M |
| Capital Expenditures (CapEx) | $97.9K | $66.5K | — |
| Free Cash Flow (FCF) | $4.8M | -$678.6K | $6.1M |
| FCF Margin % | 10.9% | -1.8% | 15.4% |
| Return on Invested Capital (ROIC %) | -16.4% | -45.0% | — |
| Cash & Short-Term Equivalents | $11.4M | $18.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $24.9M | $22.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CPIX.